Non-invasive IGFBP1, IGFBP2 biomarkers as predictors and outcomes of usual interstitial pneumonia (UIP) therapeutic response

The Egyptian Journal of Bronchology

Table 3 Comparison between UIP patient before and after treatment as regards IGFBP1 and IGFBP2 in both serum and BAL, 6MWT, and SPaO2

Parameters	UIP group (n = 23)		Paired t	P
Parameters	Before treatment, mean ± SD	After treatment, mean ± SD	Paired t	P
IGFBP1 in serum (mmol/l)	274.5 ± 31.1	257.8 ± 33.7	5.54	0.000*
IGFBP2 in serum (mmol/l)	256.2 ± 54.5	185.0 ± 37.3	5.63	0.000*
IGFBP1 in BAL (mmol/l)	225.9 ± 27.3	221.7 ± 29.2	0.95	0.351
IGFBP2 in BAL (mmol/l)	191.4 ± 27.7	149.6 ± 24.3	6.16	0.000*
6MWT	185.0 ± 10.8	216.6 ± 41.7	− 3.48	0.002*
SPaO2	83.0 ± 1.7	88.6 ± 4.5	− 6.19	0.000*

IGFBP1 insulin-like growth factor binding protein 1, IGFBP2 insulin-like growth factor binding protein 2, BAL bronchoalveolar lavage, 6MWT 6 min walking test, SPaO2 O2 saturation
*The level of significance was accepted at p ≤ 0.05